Status:

RECRUITING

Lessening Organ Dysfunction With VITamin C in Septic ARDS

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Septic

Acute Respiratory Distress Syndrome

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The primary objective of the study aims to compare the effect of high-dose intravenous vitamin C vs. placebo on a composite of death or persistent organ dysfunction - defined as continued dependency o...

Detailed Description

Treatment options for sepsis complicated by ARDS are limited to antimicrobials and supportive care (intravenous fluids, vasopressors, mechanical ventilation and renal replacement therapy). Recent prel...

Eligibility Criteria

Inclusion

  • Patients ≥18 years;
  • Admitted to ICU with proven or suspected infection as the main diagnosis;
  • Currently treated with a continuous intravenous infusion of vasopressors (norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine);
  • Presenting with Acute Respiratory Distress Syndrome
  • Patient who has signed an informed and written consent, whenever he/she is capable of consent, if not ascent from his/her representant whenever he/she is present at time of screening for inclusion
  • Affiliation to a social security system or to an universal health coverage (Couverture Maladie Universelle, CMU).
  • Patients under guardianship or curatorship will be included.
  • Patients in case of simple emergency (legal definition) will be included.

Exclusion

  • \> 24 hours of intensive care unit (ICU) admission;
  • Known Glucose-6-phosphate dehydrogenase (G6PD) deficiency;
  • Pregnancy;
  • Known allergy to vitamin C;
  • Known kidney stones within the past 1 year;
  • Received any intravenous vitamin C during this hospitalization unless incorporated in parenteral nutrition;
  • Expected death or withdrawal of life-sustaining treatments within 48 hours;
  • Previously enrolled in this study;
  • Previously enrolled in a trial for which co-enrolment is not allowed (co-enrolment to be determined case by case).

Key Trial Info

Start Date :

July 22 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2024

Estimated Enrollment :

800 Patients enrolled

Trial Details

Trial ID

NCT04404387

Start Date

July 22 2022

End Date

July 1 2024

Last Update

January 31 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department Intensive Care Unit, Hospital Raymond Poincaré - APHP

Garches, France, 92100